Fragile X syndrome (FXS) is a rare genetic disorder caused due the mutations in the Fragile X mental retardation 1 (FMR1) gene. Also known as Martin-Bell syndrome, the disease occurs due to the absence of a protein – Fragile X mental retardation protein (FMRP) – required for normal development of the body.
DelveInsight’s ‘Fragile X Syndrome Epidemiology Forecast to 2030’ report proofers an exhaustive coverage of the disease, listing down aetiology, pathophysiology, symptoms, causes, and prevailing trends.
The report outlays a focused view on historical and forecasted Fragile X Syndrome (FXS) epidemiology, presenting total cases, diagnosed pool, prevalence and incidence of the condition in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan) for the Study Period – 2017-30.
Fragile X Syndrome Epidemiology – What our analysts say
The Centers for Disease Control and Prevention estimated Fragile X Syndrome incidence is around 1.4 per 10,000 males and 0.9 per 10,000 females.
Moreover, geography-wise, the FXS epidemiological trends revealed 1 in 4000 males and 1 in 6000-8000 females are affected by FXS in the US.
The Fragile X Syndrome epidemiology data is proffered by studying all the present literature through all the divisions for better understanding of the upcoming Fragile X Syndrome trends in the decade, with views of key opinion leaders.
The report covers 3 year historical and 11-year Fragile X Syndrome forecasted analysis in the 7MM, with the data being presented in graphical, tabular and easy to understand view for clear picture and understanding of the Fragile X Syndrome epidemiological model and trends.
Fragile X Syndrome Report Highlights
- 11-Year Forecast of Fragile X Syndrome (FXS) epidemiology
- 7MM Coverage
- Fragile X Syndrome (FXS) total cases
- Fragile X Syndrome (FXS) cases according to segmentation
- Fragile X Syndrome (FXS) Diagnosed cases
Table of Contents
1. Key Insights
2. Executive Summary of Fragile X Syndrome (FXS)
3. Fragile X Syndrome (FXS): Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
*The table of contents is not exhaustive; will be provided in the final report
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.
Browse through our vast repository from here.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/